You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):普瑞巴林膠囊獲藥品註冊證書
格隆匯 11-10 16:52

格隆匯11月10日丨華潤雙鶴(600062.SH)公佈,近日,公司收到了國家藥品監督管理局頒發的普瑞巴林膠囊《藥品註冊證書》,批准該藥品生產。

普瑞巴林膠囊原研生產廠家為美國輝瑞製藥公司,商品名為“LYRICA®”,2004年7月在歐盟獲得批准上市,2004年10月在美國獲得FDA批准,2010年在國內批准上市。根據美國輝瑞製藥公司已發佈的2019年報顯示,“LYRICA®”2019年度全球銷售額為33.21億美元。

國際市場,根據Pharmarket數據顯示,2019年該藥品銷售額為72億美元,主要生產廠商有PFIZER、NEURAXPHARM、TEVA、NOVARTIS、MYLAN。

中國境內,已批准上市的該藥品生產企業有3家,其中有1家未形成市場銷售。國內市場,根據米內網數據顯示,2019年該藥品銷售總額(終端價)為3.37億元人民幣;企業份額排名分別為:輝瑞製藥有限公司60.08%;重慶賽維藥業39.92%。

截至本公告日,華潤雙鶴針對該藥品研發投入約為人民幣3,056萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account